Senergy (selamectin) Topical Parasiticide for Dogs 20.1-40 lbs Medium (12 Dose) - [Heartworm Prevention]

Senergy is a veterinary medication used for cats and dogs to prevent and treat a wide range of parasitic infestations. It offers broad-spectrum protection against fleas, ticks, ear mites, heartworms, hookworms, and roundworms. The easy-to-apply topical solution is administered monthly and is recommended by veterinarians for its proven efficacy in safeguarding pets' health.

Key Benefits:

• Comprehensive Parasite Control: Senergy provides broad-spectrum protection, effectively targeting and preventing various external parasites such as fleas and ticks, as well as internal parasites like heartworms, hookworms, and roundworms.
• Heartworm Disease Prevention: The medication helps prevent heartworm disease, a potentially life-threatening condition transmitted through mosquito bites, ensuring the heart and overall health of your pet.
• Convenient Topical Application: Senergy comes in a user-friendly spot-on formulation, making it easy to apply directly to your pet's skin. It dries quickly and leaves no greasy residue.
• Monthly Dosage: With a monthly application, Senergy ensures continuous protection against parasitic infestations, offering peace of mind for pet owners.
• Trusted by Veterinarians: Senergy is a veterinarian-recommended product, backed by extensive research and clinical studies, ensuring its safety and effectiveness.
• Suitable for Multi-Pet Households: The formulation is safe for use in both cats and dogs, making it a convenient option for households with multiple pets.
• Improved Quality of Life: By preventing and treating parasitic infestations, Senergy helps enhance your pet's well-being, promoting a healthier and happier life.

Indications:

1. Flea Infestations: Senergy is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) in cats and dogs. It effectively eliminates adult fleas and prevents new infestations for up to one month.
2. Tick Infestations: The topical solution is used to treat and control tick infestations in dogs, targeting common species such as the American dog tick (Dermacentor variabilis) and the black-legged tick (Ixodes scapularis).
3. Ear Mite Infestations: Senergy is indicated for the treatment of ear mite (Otodectes cynotis) infestations in cats and dogs. It helps eliminate these pesky parasites, providing relief from itching and discomfort.
4. Sarcoptic Mange: In dogs, Senergy is used for the treatment of sarcoptic mange (Sarcoptes scabiei), a contagious skin condition caused by mites.
5. Heartworm Disease Prevention: Senergy is indicated for the prevention of heartworm disease (Dirofilaria immitis) in cats and dogs. Monthly administration of the medication helps protect pets from the potentially serious and life-threatening effects of heartworm infestations.
6. Intestinal Worm Infestations: For dogs, Senergy is used to treat and control adult hookworms (Ancylostoma caninum), adult roundworms (Toxocara canis), and adult whipworms (Trichuris vulpis).

It's important to note that Senergy (selamectin) Topical is intended for use in cats and dogs only, and appropriate dosing based on the pet's weight and species should be strictly followed. To ensure the safety and effectiveness of the treatment, it is essential to consult with a veterinarian before starting or changing any medication regimen for your pet.

How it works:

1. Fleas and Ticks: Selamectin disrupts the normal functioning of the flea and tick nervous system. It binds to specific receptors in their nerve cells, causing a disruption in the transmission of nerve signals. This interference leads to paralysis and eventual death of the parasites. It works on both adult fleas and ticks as well as their larvae and eggs.
2. Heartworms: Senergy prevents heartworm disease by killing the larval stages of heartworms (microfilariae) that are transmitted to pets through mosquito bites. By stopping the development of these larvae, it prevents them from maturing into adult heartworms, which would otherwise reside in the heart and pulmonary arteries of the pet, potentially causing severe health issues.
3. Ear Mites and Sarcoptic Mange: Selamectin's neurotoxic effect also extends to ear mites and mites causing sarcoptic mange. By affecting their nervous systems, it eliminates these parasitic mites, providing relief from itching and irritation.
4. Intestinal Worms: When administered orally for the treatment of intestinal worm infestations in dogs, selamectin disrupts the nerve activity in the parasites, leading to paralysis and elimination of adult hookworms, roundworms, and whipworms.

Senergy is designed for topical application, and after it is applied to the skin, the active ingredient is absorbed into the bloodstream. From there, it circulates throughout the pet's body, reaching different tissues and organs. This systemic distribution ensures that the medication can target both external parasites on the skin and internal parasites affecting various parts of the body.

It's important to use Senergy as directed by your veterinarian, following the recommended dosing schedule for your pet's weight and species. Regular monthly application of Senergy is essential to maintain effective protection against parasites and ensure the overall health and well-being of your furry companion.

Active Ingredients: The content of each tube is formulated to provide a minimum of 2.7 mg/lb (6 mg/kg) of body weight of selamectin. The chemical composition of selamectin is (5Z,25S)-25-cyclohexyl-4'-O-de(2,6-dideoxy-3-O-methyl-?-L-arabinohexopyranosyl)-5-demethoxy-25-de(1-methylpropyl)-22,23-dihydro-5-hydroxyiminoavermectin A1a.

View Senergy Drug Facts Sheet.

The recommended minimum dose is 2.7 mg selamectin per pound (6 mg/kg) of body weight.

Administer the entire contents of a single dose tube (or two tubes used in combination for dogs weighing over 130 pounds) of SENERGY topically in accordance with the following tables. (See Administration for the recommended treatment intervals.)

For cats over 22 lbs use the appropriate combination of tubes.

For dogs over 130 lbs use the appropriate combination of tubes. Recommended for use in dogs 6 weeks of age and older and in cats 8 weeks of age and older.

Administration:

A veterinarian or veterinary technician should demonstrate or instruct the pet owner regarding the appropriate technique for applying SENERGY topically to dogs and cats prior to first use. Remove the tube from the package and hold upright with the lot and expiration at the bottom. Bend the tip back until it snaps off. To administer the product, part the hair on the back of the animal at the base of the neck in front of the shoulder blades until the skin is visible. Place the tip of the tube on the skin and squeeze the tube 3 or 4 times to empty its entire contents directly onto the skin in one spot. Keeping the tube squeezed, drag it away from the liquid and lift to remove. Check the tube to ensure that it is empty. Do not massage the product into the skin. Due to alcohol content, do not apply to broken skin. Avoid contact between the product and fingers. Do not apply when the haircoat is wet. Bathing or shampooing the dog 2 or more hours after treatment will not reduce the effectiveness of SENERGY against fleas or heartworm. Bathing or shampooing the cat 2 hours after treatment will not reduce the effectiveness of SENERGY against fleas. Bathing or shampooing the cat 24 hours after treatment will not reduce the effectiveness of SENERGY against heartworm. Stiff hair, clumping of hair, hair discoloration, or a slight powdery residue may be observed at the treatment site in some animals. These effects are temporary and do not affect the safety or effectiveness of the product. Discard empty tubes in your ordinary household refuse.

Flea Control in Dogs and Cats

For the prevention and control of flea infestations, SENERGY should be administered at monthly intervals throughout the flea season, starting one month before fleas become active. In controlled laboratory studies >98% of fleas were killed within 36 hours. Results of clinical field studies using selamectin monthly demonstrated >90% control of flea infestations within 30 days of the first dose. Dogs and cats treated with selamectin, including those with pre-existing flea allergy dermatitis, showed improvement in clinical signs associated with fleas as a direct result of eliminating the fleas from the animals and their environment.

If the dog or cat is already infested with fleas when the first dose of selamectin is administered, adult fleas on the animal are killed and no viable fleas hatch from eggs after the first administration. However, an environmental infestation of fleas may persist for a short time after beginning treatment with selamectin because of the emergence of adult fleas from pupae.

Heartworm Prevention in Dogs and Cats

For the prevention of heartworm disease, SENERGY must be administered on a monthly basis. SENERGY may be administered year-round or at least within one month after the animal’s first exposure to mosquitoes and monthly thereafter until the end of the mosquito season. The final dose must be given within one month after the last exposure to mosquitoes. If a dose is missed and a monthly interval between dosing is exceeded then immediate administration of SENERGY and resumption of monthly dosing will minimize the opportunity for the development of adult heartworms. When replacing another heartworm preventive product in a heartworm disease prevention program, the first dose of SENERGY must be given within a month of the last dose of the former medication.

Selamectin, the active ingredient in SENERGY, is a macrocyclic lactone compond. These componds effectively prevent the development of adult heartworms when administered to dogs and cats within one month of exposure to infective (L₃) Dirofilaria immitis larvae. Efficacy of macrocyclic lactones decreases below 100% in dogs, however, if first administered >2 months after exposure to infective larvae. Thus, in heartworm endemic regions, delaying initiation of heartworm prevention using SENERGY beyond 2 months of first exposure to infective larvae (e.g.,starting puppies and kittens at >8 weeks of age), or gaps of >2 months in the administration of SENERGY during periods of heartworm transmission, increases the risk of the animal acquiring heartworms. Animals with unknown heartworm history that test negative for heartworms prior to the initiation of SENERGY may be harboring pre-patent infections at the time SENERGY was started. Testing such animals 3-4 months after initiation of SENERGY would be necessary to confirm their negative heartworm status.At the discretion of the veterinarian, cats ≥6 months of age may be tested to determine the presence of existing heartworm infections before beginning treatment with SENERGY. Cats already infected with adult heartworms can be given SENERGY monthly to prevent further infections.

Ear Mite Treatment in Dogs and Cats

For the treatment of ear mite (O. cynotis) infestations in dogs and cats, SENERGY should be administered once as a single topical dose. A second monthly dose may be required in some dogs. Monthly use of SENERGY will control any subsequent ear mite infestations. In the clinical field trials ears were not cleaned, and many animals still had debris in their ears after the second dose. Cleansing of the infested ears is recommended to remove the debris.

Sarcoptic Mange Treatment in Dogs

For the treatment of sarcoptic mange (S. scabiei) in dogs, SENERGY should be administered once as a single topical dose. A second monthly dose may be required in some dogs. Monthly use of SENERGY will control any subsequent sarcoptic mange mite infestations. Because of the difficulty in finding sarcoptic mange mites on skin scrappings, effectiveness assessments also were based on resolution of clinical signs. Resolution of the pruritus associated with the mite infestations was observed in approximately 50% of the dogs 30 days after the first treatment and in approximately 90% of the dogs 30 days after the second monthly treatment.

Tick Control in Dogs

For the control of tick (Dermacentor variabilis) infestations in dogs, SENERGY should be administered on a monthly basis. In heavy tick infestations, complete efficacy may not be achieved after the first dose. In these cases, one additional dose may be administered two weeks after the previous dose, with monthly dosing continued thereafter.

Nematode Treatment in Cats

For the treatment and control of intestinal hookworm (A. tubaeforme) and roundworm (T. cati) infections, SENERGY should be applied once as a single topical dose.

Caution:

US Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Warnings:

Not for human use. Keep out of the reach of children. In humans, SENERGY may be irritating to skin and eyes. Reactions such as hives, itching and skin redness have been reported in humans in rare instances. Individuals with known hypersensitivity to SENERGY should use the product with caution or consult a health care professional. SENERGY contains isopropyl alcohol and the preservative butylated hydroxytoluene (BHT). Wash hands after use and wash off any product in contact with the skin immediately with soap and water. If contact with eyes occurs, then flush eyes copiously with water. In case of ingestion by a human, contact a physician immediately. The safety data sheet (SDS) provides more detailed occupational safety information. To report suspected adverse drug events, for technical assistance or to obtain a copy of the SDS, contact Virbac AH, Inc. at 1-800-338-3659 or us.virbac.com.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae.

Flammable - Keep away from heat, sparks, open flames or other sources of ignition.

Do not use in sick, debilitated or underweight animals (see safety).

Precautions:

Prior to administration of SENERGY, dogs should be tested for existing heartworm infections. At the discretion of the veterinarian, infected dogs should be treated to remove adult heartworms. Selamectin is not effective against adult D. immitis and, while the number of circulating microfilariae may decrease following treatment, selamectin is not effective for microfilariae clearance.Hypersensitivity reactions have not been observed in dogs with patent heartworm infections administered three times the recommended dose of selamectin. Higher doses were not tested.

Adverse Reactions:

Pre-approval clinical trials:

Following treatment with selamectin, transient localized alopecia with or without inflammation at or near the site of application was observed in approximately 1% of 691 treated cats. Other signs observed rarely (≤0.5% of 1743 treated cats and dogs) included vomiting, loose stool or diarrhea with or without blood, anorexia, lethargy, salivation, tachypnea, and muscle tremors.

Post-approval experience:

In addition to the aforementioned clinical signs that were reported in pre-approval clinical trials, there have been reports of pruritus, urticaria, erythema, ataxia, fever, and rare reports of death. There have also been rare reports of seizures in dogs (see warnings).

Safety:

Selamectin has been tested safe in over 100 different pure and mixed breeds of healthy dogs and over 15 different pure and mixed breeds of healthy cats, including pregnant and lactating females, breeding males and females, puppies six weeks of age and older, kittens eight weeks of age and older, and avermectin-sensitive collies. A kitten, estimated to be 5-6 weeks old (0.3 kg), died 8 1/2 hours after receiving a single treatment of selamectin at the recommended dosage. The kitten displayed clinical signs which included muscle spasms, salivation and neurological signs. The kitten was a stray with an unknown history and was malnourished and underweight (see warnings).

DOGS: In safety studies, selamectin was administered at 1, 3, 5, and 10 times the recommended dose to six-week-old puppies, and no adverse reactions were observed. The safety of selamectin administered orally also was tested in case of accidental oral ingestion. Oral administration of selamectin at the recommended topical dose in 5 to 8-month-old beagles did not cause any adverse reactions. In a pre-clinical study selamectin was dosed orally to ivermectin-sensitive collies. Oral administration of 2.5, 10, and 15 mg/kg in this dose escalating study did not cause any adverse reactions; however, eight hours after receiving 5 mg/kg orally, one avermectin-sensitive collie became ataxic for several hours, but did not show any other adverse reactions after receiving subsequent doses of 10 and 15 mg/kg orally. In a topical safety study conducted with avermectin-sensitive collies at 1, 3 and 5 times the recommended dose of selamectin, salivation was observed in all treatment groups, including the vehicle control. Selamectin also was administered at 3 times the recommended dose to heartworm infected dogs, and no adverse effects were observed.

CATS: In safety studies, selamectin was applied at 1, 3, 5, and 10 times the recommended dose to six-week-old kittens. No adverse reactions were observed. The safety of selamectin administered orally also was tested in case of accidental oral ingestion. Oral administration of the recommended topical dose of selamectin to cats caused salivation and intermittent vomiting. Selamectin also was applied at 4 times the recommended dose to patent heartworm infected cats, and no adverse reactions were observed.In well-controlled clinical studies, selamectin was used safely in animals receiving other frequently used veterinary products such as vaccines, anthelmintics, antiparasitics, antibiotics, steroids, collars, shampoos and dips.

Storage:

Store below 25°C (77°F).